Tumor immune microenvironment of EGFR-mutant non-small-cell lung cancer and its impact on therapeutic efficacy

Immunotherapy. 2020 May;12(7):431-437. doi: 10.2217/imt-2019-0213. Epub 2020 Apr 22.

Authors

Yoshiya Matsumoto^{1

2}, Yasuhiro Koh²

Affiliations

¹ Department of Respiratory Medicine, Graduate School of Medicine, Osaka City University, Osaka, Japan.
² Internal Medicine III, Wakayama Medical University, Wakayama, Japan.

PMID: 32316809
DOI: 10.2217/imt-2019-0213

No abstract available

Keywords: epidermal growth factor receptor; non-small-cell lung cancer; tumor microenvironment; tumor mutational burden.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / metabolism
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics*
Carcinoma, Non-Small-Cell Lung / immunology
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Humans
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics*
Lung Neoplasms / immunology
Mutation
Protein Kinase Inhibitors / therapeutic use
Treatment Outcome
Tumor Microenvironment / genetics
Tumor Microenvironment / immunology*

Substances

B7-H1 Antigen
CD274 protein, human
Immune Checkpoint Inhibitors
Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors